Advanced Regimens
Biological & Targeted Synthetic DMARD Therapies
Day-care infusion suite for Anti-TNF, Tocilizumab, Rituximab, and JAK inhibitors.
Personalized infusion and subcutaneous biological therapies targeting specific TNF-alpha, IL-6, B-cell, and JAK-STAT pathways for resistant autoimmune diseases.
Book ConsultationClinical Highlights & Procedures
-
In-house day-care Infusion Suite with continuous vital monitoring
-
Anti-TNF, Anti-IL-6 (Tocilizumab), Anti-CD20 (Rituximab) protocol administration
-
JAK Inhibitors (Tofacitinib, Upadacitinib) dosing and safety monitoring
-
Pre-biologic screening (TB Quantiferon, Viral Markers, Vaccination protocols)